Showing 1-10 of 132 Results
Katherine N. Alfieri, Ph.D.
Program Manager, ChEM-H Operations
BioDr. Katherine Alfieri joined Stanford ChEM-H in February 2016 as the Program Manager. She develops and manages ChEM-H’s training programs, including undergraduate, predoctoral, and postdoctoral programs.
Justin P. Annes M.D., Ph.D.
Assistant Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsThe ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders
The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.
(1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.
(2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.
HEREDIATY PARAGAGLIOMA SYNDROME
The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.
As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.
K. K. Lee Professor in the School of Engineering and Professor, by courtesy, of Materials Science and Engineering and of Chemistry
BioZhenan Bao joined Stanford University in 2004. She is currently a K.K. Lee Professor in Chemical Engineering, and with courtesy appointments in Chemistry and Material Science and Engineering. She is a member of the National Academy of Engineering and National Academy of Inventors. She founded the Stanford Wearable Electronics Initiative (eWEAR) and is the current faculty director. She is also an affiliated faculty member of Precourt Institute, Woods Institute, ChEM-H and Bio-X. Professor Bao received her Ph.D. degree in Chemistry from The University of Chicago in 1995 and joined the Materials Research Department of Bell Labs, Lucent Technologies. She became a Distinguished Member of Technical Staff in 2001. Professor Bao currently has more than 400 refereed publications and more than 60 US patents. She served as a member of Executive Board of Directors for the Materials Research Society and Executive Committee Member for the Polymer Materials Science and Engineering division of the American Chemical Society. She was an Associate Editor for the Royal Society of Chemistry journal Chemical Science, Polymer Reviews and Synthetic Metals. She serves on the international advisory board for Advanced Materials, Advanced Energy Materials, ACS Nano, Accounts of Chemical Reviews, Advanced Functional Materials, Chemistry of Materials, Chemical Communications, Journal of American Chemical Society, Nature Asian Materials, Materials Horizon and Materials Today. She is one of the Founders and currently sits on the Board of Directors of C3 Nano Co., a silicon valley venture funded company. She is Fellow of AAAS, ACS, MRS, SPIE, ACS POLY and ACS PMSE. She was a recipient of the L'Oreal UNESCO Women in Science Award in 2017. She was awarded the ACS Applied Polymer Science Award in 2017, ACS Creative Polymer Chemistry Award in 2013 ACS Cope Scholar Award in 2011, and was selected by Phoenix TV, China as 2010 Most influential Chinese in the World-Science and Technology Category. She is a recipient of the Royal Society of Chemistry Beilby Medal and Prize in 2009, IUPAC Creativity in Applied Polymer Science Prize in 2008, American Chemical Society Team Innovation Award 2001, R&D 100 Award, and R&D Magazine Editors Choice Best of the Best new technology for 2001. She has been selected in 2002 by the American Chemical Society Women Chemists Committee as one of the twelve Outstanding Young Woman Scientist who is expected to make a substantial impact in chemistry during this century. She is also selected by MIT Technology Review magazine in 2003 as one of the top 100 young innovators for this century. She has been selected as one of the recipients of Stanford Terman Fellow and has been appointed as the Robert Noyce Faculty Scholar, Finmeccanica Faculty Scholar and David Filo and Jerry Yang Faculty Scholar.
Professor of Neurobiology, of Developmental Biology, of Neurology and, by courtesy, of Ophthalmology
Current Research and Scholarly InterestsOur lab is interested in the neuronal-glial interactions that underlie the development and function of the mammlian central nervous system.
Assistant Professor of Genetics
Current Research and Scholarly InterestsWe are interested in the mechanism by which bacterial toxins, viruses, and protein aggregates hijack the secretory pathway and kill cells. More broadly, we investigate how diverse stresses (biological, chemical) signal to the apoptotic machinery.
To pursue these interests, we develop widely applicable new technologies to screen and measure genetic interactions; these include high-complexity shRNA libraries, which have allowed the first systematic genetic interaction maps in mammalian cells.
Alfred Woodley Salter and Mabel Smith Salter Endowed Professor in Pediatrics
Current Research and Scholarly Interests1. Role of the G protein coupled receptors in regulating mitochondrial structure and function.
2. Differences between R and L ventricular responses to stress, including gene expression and miR regulation.
3. Using iPSC-derived myocytes to understand heart failure and congenital heart disease.
4. Tools for evaluation of cardiac physiology in transgenic mice and isolated cardiomyocytes.
5. Anti-body mediated rejection.
6. Biomarkers for post-transplant lymphoproliferative disorder.
Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Radiology and of Chemical and Systems Biology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, and the ACS Award in Pure Chemistry, among many others. Her efforts in undergraduate education have earned the UC Berkeley Distinguished Teaching Award and the Donald Sterling Noyce Prize for Excellence in Undergraduate Teaching.
Today, the Bertozzi Group at Stanford studies the glycobiology underlying diseases such as cancer, inflammatory disorders such as arthritis, and infectious diseases such as tuberculosis. The work has advanced understanding of cell surface oligosaccharides involved in cell recognition and inter-cellular communication.
Dr. Bertozzi's lab also develops new methods to perform controlled chemical reactions within living systems. The group has developed new tools for studying glycans in living systems, and more recently nanotechnologies for probing biological systems. Such "bioorthoganol" chemistries enable manipulation of biomolecules in their living environment.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi founded Redwood Bioscience of Emeryville, California, and has served on the research advisory board of GlaxoSmithKline.
Assistant Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur lab uses chemical, biochemical, and cell biological methods to study protease function in human disease. Projects include:
1) Design and synthesis of novel chemical probes for each of the primary protease families.
2) Understanding the role of proteolysis in the life cycle of the human parasites, Plasmodium falciparum and Toxoplasma gondii.
3) Defining the specific functional roles of proteases during the process of tumorogenesis.
4) In vivo imaging of protease activity
Burt and Marion Avery Professor of Immunology
Current Research and Scholarly InterestsWe are intereseted in the interaction between the protozoan parasite Toxoplasma gondii and its mammalian host. We use a combination of molecular and genetic tools to understand how this obligate intracellular parasite can invade almost any cell it encounters, how it co-opts a host cell once inside and how it evades the immune response to produce a life-long, persistent infection.